Drucker Wealth 3.0 LLC Has $1.54 Million Holdings in Amgen Inc. $AMGN

Drucker Wealth 3.0 LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 33.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,373 shares of the medical research company’s stock after selling 2,160 shares during the period. Drucker Wealth 3.0 LLC’s holdings in Amgen were worth $1,539,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. High Note Wealth LLC grew its holdings in shares of Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after buying an additional 28 shares in the last quarter. TAGStone Capital Inc. lifted its stake in Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after acquiring an additional 28 shares in the last quarter. Verus Capital Partners LLC boosted its position in Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management grew its stake in Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares in the last quarter. Finally, Breakwater Capital Group grew its stake in Amgen by 1.4% during the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock valued at $717,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AMGN. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Morgan Stanley upped their price objective on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. Argus cut their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Canaccord Genuity Group initiated coverage on shares of Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price for the company. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $354.42.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Amgen Stock Performance

AMGN opened at $360.55 on Tuesday. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The company has a market cap of $194.59 billion, a PE ratio of 25.09, a price-to-earnings-growth ratio of 3.60 and a beta of 0.42. The stock has a 50-day moving average of $340.92 and a 200-day moving average of $346.71. Amgen Inc. has a 52-week low of $269.77 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue was up 5.8% compared to the same quarter last year. During the same period last year, the business earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.